BETADINE® IN CHEMICAL PLEURODESIS
CLAUDIU NISTOR1*, AURELIAN-EMIL RANETTI2, ADRIAN
CIUCHE1, DANIEL PANTILE1, LAURA–MARIANA CONSTANTIN3,
ROXANA BRÎNCOVEANU4
1Department of Thoracic Surgery, “Dr. Carol Davila” Central Military
Emergency University Hospital, Bucharest, Romania
2Department of Endocrinology, “Dr. Carol Davila” Central Military
Emergency University Hospital, Bucharest, Romania
3Department of Laboratory Medicine, “Dr. Carol Davila” Central
Military Emergency University Hospital, Bucharest, Romania
4Carol Davila University of Medicine and Pharmacy, Bucharest,
Romania
*corresponding author: ncd58@yahoo.com
Download Full Article

Abstract:

Malignant pleural effusions (MPEs) represent a common complication which can
occur in any neoplastic disease. Between October 2012 and December 2013 we performed
a prospective study aimed to establish the adequate treatment for malignant pleural
effusions. 85 patients were included in this study, diagnosed and treated in the Thoracic
Surgery Department of the Central Military Emergency University Hospital. 46 patients
underwent chemical pleurodesis with betadine® (through thoracoscopic surgery – 30
patients – or through a chest drainage tube – 16 patients), while for 39 patients talcum
powder was chosen as the agent for pleurodesis (through thoracoscopic surgery – 28
patients – or through a chest drainage tube – 11 patients with major surgical risk). The most
frequent cancers with secondary MPEs were lung cancers (50 patients). The efficiency of
the two methods was the same. The most used chemical pleurodesis procedure was the
thoracoscopic surgery (58 patients). The most used agent for pleurodesis was Betadine® (30
patients)...

Top